Congressional Legislation Seeks to Ensure “Equitable Treatment” in the 340B Program
Congressional Legislation Seeks to Ensure “Equitable Treatment” in the 340B Program
Authored by Alan J. Arville, J.D. and Kala K. Shankle, J.D.of Epstein Becker Green In…
Top 3 Areas Where CostCheck™ Customers Are Seeing the Most Savings.
Top 3 Areas Where CostCheck™ Customers Are Seeing the Most Savings. By Hannah Kanfer BluesightⓇ …
What Does ASHP’s Revised Drug Diversion Guidelines Mean for Your Hospital?
What Does ASHP’s Revised Drug Diversion Guidelines Mean for Your Hospital? By: Sandy Still, PharmD…
Drug Shortages, Variance Spikes and Other Key Takeaways from the Diversion Quarterly.
By Hannah Kanfer BluesightⓇ released the Q2 2022 Diversion Quarterly, sharing data from its…
Why a Next-Generation Drug Diversion Solution is Vital for Hospitals.
By: Doug Zurawski, Pharm.D. Drug diversion is any act or deviation that removes a…
The Pandemic’s Continued Strain On Labor And Other Key Takeaways From The Diversion Trends Report
Kit Check recently released its 2022 Diversion Trends Report. In the report, Kit Check analyzed…
KitCheck™ Releases New Medication Pricing Information Function as First Step Towards Further Product Integration.
By Hannah Kanfer KitCheck recently released a new feature that integrates medication pricing information into…
New Bill Will Help Prevent Opioid Deaths by Making Opioid Overdose Medications More Accessible.
By Hannah Kanfer The opioid epidemic has been a long battle in the United…
Early Recognition and Culture of Safety, both Vital to Catching and Preventing Diversion.
Bluesight’s top takeaways from NADDI 2022. By Hannah Kanfer This past week, BluesightⓇ attended the…
The Evolution of 340B and the Challenges it Faces; is Technology the Answer?
The Evolution of 340B and the Challenges it Faces; is Technology the Answer? By Hannah…